A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +117 locations
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Nabilone for Agitation Blinded Intervention Trial
NCT04516057
Recruiting
This study will look at whether nabilone is an effective treatment for agitation in Alzheimer's disease (AD) patients. Agitation is highly prevalent in patients with AD and is one of the most distressing and challenging-to-treat symptoms. Agitation is associated with faster progression to institutionalization, increased caregiver burden, poorer quality of life, and increased risk of death. In addition, current pharmacological options show only modest efficacy and elevated risks of adverse events... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
04/23/2025
Locations: University of Calgary, Calgary, Alberta +5 locations
Conditions: Alzheimer Disease, Agitation
Register for Updates
Temporal Interference and Depression
NCT05295888
Recruiting
Major Depressive Disorder (MDD) has a high prevalence, is the leading cause of disability, and currently available interventions are associated with side effects and high treatment resistance. There is an urgent need for the development of novel interventions for MDD with alternate mechanisms of action. Temporal Interference (TI) stimulation is a newly emerging form of transcranial alternating current stimulation (tACS) that involves the application of two high-frequency currents at slightly dif... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/22/2025
Locations: Interventional Psychiatry Program, St. Michael's Hospital - Unity Health Toronto, Toronto, Ontario
Conditions: Major Depressive Disorder
Register for Updates
Perioperative Vitamin C to Reduce Persistent Pain After Total Knee Arthroplasty
NCT06123715
Recruiting
Phase II Multicentre, pilot, parallel-group, blinded, 1:1 randomized controlled trial to determine the feasibility of conducting a larger definitive trail of using vitamin C to reduce persistent pain in patients undergoing total knee arthroplasty surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Sunnybrook - Holland Centre, Toronto, Ontario +2 locations
Conditions: Chronic Pain, Knee Pain Chronic, Post Operative Pain
Register for Updates
Conditioning SCID Infants Diagnosed Early
NCT03619551
Recruiting
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related dono... Read More
Gender:
ALL
Ages:
Between 0 years and 2 years
Trial Updated:
04/22/2025
Locations: Univeristy of Alabama at Birmingham, Birmingham, Alabama +51 locations
Conditions: SCID
Register for Updates
Intra-Operative Adductor Canal Blocks
NCT05601427
Recruiting
Adductor canal blocks (ACB) have been recommended in total knee arthroplasty (TKA) to provide better control of post-operative pain, facilitate early ambulation, and reduce length of stay in the hospital. ACB is typically done before surgery by an anesthesiologist, which may increase time per case, cost, and requires the specialized skills of an anesthesiologist trained in regional anesthesia. Recent studies have suggested that surgeons can safely and reliably administer the adductor canal block... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: The Ottawa Hospital, Ottawa, Ontario
Conditions: Knee Osteoarthritis, Knee Arthritis, Knee Pain Chronic, Anesthesia
Register for Updates
Pilot Trial of Virtual and In-person STEP2
NCT06326554
Recruiting
The goal of this clinical trial is to assess the feasibility of offering oncology patients a referral to the outpatient palliative care clinic based on virtual symptom screening before oncology clinic appointments, and to qualitatively explore factors patients consider when deciding to accept or defer a visit to this clinic. Participants will be asked to complete questionnaires assessing quality of life, symptom burden, depression, anxiety, and satisfaction with care at baseline, 2, 4, and 6 mo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: University Health Network, Toronto, Ontario
Conditions: Oncology
Register for Updates
Prebiotics in Patients With Type 1 Diabetes
NCT04963777
Recruiting
Evidence suggests that prebiotic fibre can correct dysbiosis, reduce intestinal permeability and improve glycemic control. The investigators hypothesize that microbial changes induced by prebiotics contribute to gut and endocrine adaptations that reduce glucose fluctuations, including less hyper- and hypoglycemia in type 1 diabetes (T1D). The primary objective is to compare the change in frequency of hypoglycemia from baseline to 6 months in n=144 individuals with T1D treated with a 6-month cour... Read More
Gender:
ALL
Ages:
7 years and above
Trial Updated:
04/22/2025
Locations: University of Calgary, Calgary, Alberta +2 locations
Conditions: Type 1 Diabetes
Register for Updates
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
NCT06185764
Recruiting
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/21/2025
Locations: Stanford Neuromuscular Research, San Carlos, California +25 locations
Conditions: Myotonic Dystrophy Type 1 (DM1)
Register for Updates
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
NCT04635891
Recruiting
The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD. M... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/21/2025
Locations: David Geffen School of Medicine at UCLA, Los Angeles, California +19 locations
Conditions: FSHD
Register for Updates
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941
Recruiting
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis... Read More
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
04/21/2025
Locations: Mayo Clinic Arizona, Scottsdale, Arizona +53 locations
Conditions: Prostate Cancer
Register for Updates
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
NCT03546582
Recruiting
This phase II trial with a safety run-in component will evaluate whether the addition of pembrolizumab to Stereotactic Body Radiation Therapy (SBRT) re-irradiation will improve the progression-free survival for patients with recurrent or new second primary Head and Neck Squamous Cell Carcinoma (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: University of Arizona Cancer Center - North Campus, Tucson, Arizona +20 locations
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Register for Updates